File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pulmonary hypertension secondary to systemic lupus erythematosus: Prolonged survival following treatment with intermittent low dose iloprost

TitlePulmonary hypertension secondary to systemic lupus erythematosus: Prolonged survival following treatment with intermittent low dose iloprost
Authors
KeywordsConnective tissue disease
Prostacyclin
Prostaglandin
Secondary pulmonary hypertension
Issue Date1999
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
Citation
Lupus, 1999, v. 8 n. 4, p. 328-331 How to Cite?
AbstractPulmonary hypertension (PHT) associated with systemic lupus erythematosus ISLE) has a dismal prognosis. Vasodilators and immunosuppressive therapy have been tried over the years with discouraging results. Prostacyclin (PGI2) which has potent vasodilatatory and anti-platelet effects has been demonstrated to significantly decrease pulmonary arterial pressure and pulmonary vascular resistance during acute infusion. Satisfactory response has been reported in SLE patients with PHT treated with short-term intravenous continuous PGI2 infusion. We report here a 48-month experience of the use of monthly low dose infusion of a PGI2 analogue, iloprost, in a SLE patient with pulmonary hypertension in New York Heart Association functional Class III. There was an initial haemodynamic response to an acute infusion of iloprost. Repeated infusions were followed by marked improvement in her functional status and her mean pulmonary arterial pressure dropped from 80 mmHg in the first few months and remained static at around 55 mmHg for the subsequent years.
Persistent Identifierhttp://hdl.handle.net/10722/76362
ISSN
2015 Impact Factor: 2.118
2015 SCImago Journal Rankings: 0.878
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, MYen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorLau, CSen_HK
dc.date.accessioned2010-09-06T07:20:25Z-
dc.date.available2010-09-06T07:20:25Z-
dc.date.issued1999en_HK
dc.identifier.citationLupus, 1999, v. 8 n. 4, p. 328-331en_HK
dc.identifier.issn0961-2033en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76362-
dc.description.abstractPulmonary hypertension (PHT) associated with systemic lupus erythematosus ISLE) has a dismal prognosis. Vasodilators and immunosuppressive therapy have been tried over the years with discouraging results. Prostacyclin (PGI2) which has potent vasodilatatory and anti-platelet effects has been demonstrated to significantly decrease pulmonary arterial pressure and pulmonary vascular resistance during acute infusion. Satisfactory response has been reported in SLE patients with PHT treated with short-term intravenous continuous PGI2 infusion. We report here a 48-month experience of the use of monthly low dose infusion of a PGI2 analogue, iloprost, in a SLE patient with pulmonary hypertension in New York Heart Association functional Class III. There was an initial haemodynamic response to an acute infusion of iloprost. Repeated infusions were followed by marked improvement in her functional status and her mean pulmonary arterial pressure dropped from 80 mmHg in the first few months and remained static at around 55 mmHg for the subsequent years.en_HK
dc.languageengen_HK
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.comen_HK
dc.relation.ispartofLupusen_HK
dc.rightsLupus. Copyright © Sage Publications Ltd.en_HK
dc.subjectConnective tissue diseaseen_HK
dc.subjectProstacyclinen_HK
dc.subjectProstaglandinen_HK
dc.subjectSecondary pulmonary hypertensionen_HK
dc.subject.meshAdult-
dc.subject.meshHypertension, Pulmonary - drug therapy - etiology-
dc.subject.meshIloprost - administration and dosage-
dc.subject.meshLupus Erythematosus, Systemic - complications-
dc.subject.meshVasodilator Agents - administration and dosage-
dc.titlePulmonary hypertension secondary to systemic lupus erythematosus: Prolonged survival following treatment with intermittent low dose iloprosten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0961-2033&volume=8&issue=4&spage=328&epage=331&date=1999&atitle=Pulmonary+hypertension+secondary+to+systemic+lupus+erythematosus:+prolonged+survival+following+treatment+with+intermittent+low+dose+iloprosten_HK
dc.identifier.emailMok, MY:temy@hkucc.hku.hken_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1191/096120399678847795en_HK
dc.identifier.pmid10413214-
dc.identifier.scopuseid_2-s2.0-0032969960en_HK
dc.identifier.hkuros45170en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032969960&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue4en_HK
dc.identifier.spage328en_HK
dc.identifier.epage331en_HK
dc.identifier.isiWOS:000081038800015-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats